L. casei Adjunct to DMARDs: 61% RA Remission at 24 Weeks

Rheumatoid arthritis is a chronic autoimmune disease characterized by progressive joint destruction, and its primary clinical target under treat-to-target guidelines is remission — defined as a Disease Activity Score-28 (DAS28) below 2.6. On first-line disease-modifying antirheumatic drug (DMARD) therapy alone, sustained remission is achieved in a minority of newly diagnosed patients, even during the early treatment window when intervention most meaningfully alters long-term disease trajectory. The question of whether microbial interventions — specifically live fermented milks delivering defined cultures — can shift those remission rates in a clinically meaningful way has attracted increasing research attention.

A 2025 randomized controlled trial by Barac and colleagues, published in the Journal of Infection in Developing Countries, enrolled 100 newly diagnosed RA patients and assigned them to standard DMARD therapy with or without a live-culture formula containing Lacticaseibacillus casei BLn2401 as its primary organism, alongside L. salivarius BL2201 and Bifidobacterium breve BL3406. Patients were followed for 12 months, with remission as the primary endpoint. The result was not marginal.

Key Findings

DAS28 = Disease Activity Score 28-joint count. Remission threshold: DAS28 < 2.6. HR = hazard ratio from Cox proportional hazards model. Control group received standard DMARD therapy only.

Mechanism: How L. casei Acts on Gut-Mediated Immune Dysregulation in RA

Gut Permeability, LPS Translocation, and TLR4/NF-κB Activation

The intestinal epithelium in patients with active RA shows measurable structural disruption. Tight-junction proteins — claudin-1, occludin, and zona occludens-1 — are downregulated compared to healthy controls, and serum zonulin, a validated biomarker of paracellular permeability, is elevated. This structural failure has a specific and well-characterized consequence: lipopolysaccharide (LPS), a cell-wall component of gram-negative bacteria, crosses from the intestinal lumen into systemic circulation through a process called LPS translocation. Once in circulation, LPS binds to Toll-like receptor 4 (TLR4) expressed on macrophages and dendritic cells. This binding triggers MyD88-dependent intracellular signaling through NF-κB — a transcription factor that drives the expression of IL-1β, IL-6, and TNF-α. In the synovial tissue of RA patients, this cytokine environment activates fibroblast-like synoviocytes, promotes RANKL-dependent osteoclast differentiation, and sustains the inflammatory cycle underlying cartilage erosion and bone destruction.

Lacticaseibacillus casei cultures produce short-chain fatty acids — butyrate and acetate among them — that support intestinal epithelial integrity through several routes: stimulating goblet cell mucin synthesis, promoting tight-junction protein expression, and shifting the intestinal microbiome toward a composition associated with lower Proteobacteria abundance and reduced gram-negative LPS burden. The downstream effect is a reduction in LPS translocation, less TLR4 engagement, and reduced NF-κB-driven cytokine output at the systemic level.

Th17/Treg Ratio Rebalancing and Autoimmune Suppression

Rheumatoid arthritis is characterized by a specific T-cell polarization imbalance: elevated Th17 activity and suppressed regulatory T-cell (Treg) function. Th17 cells produce IL-17A, which upregulates receptor activator of NF-κB ligand (RANKL) expression on osteoblasts and synoviocytes — directly promoting osteoclastogenesis and bone erosion — while simultaneously sustaining IL-6 production in a feedforward amplification loop. Tregs, which express the transcription factor FoxP3 and suppress immune activation through IL-10 and TGF-β signaling, are both numerically reduced and functionally impaired in active RA, leaving Th17-driven inflammation relatively unchecked.

L. casei interacts with intestinal CD103+ dendritic cells via TLR2 and TLR9 surface receptors, inducing a tolerogenic dendritic cell phenotype. These tolerogenic dendritic cells direct naive T-cell differentiation preferentially toward FoxP3+ Tregs rather than Th17 cells, shifting the Th17/Treg ratio toward immune regulation. The cytokine profile documented by Barac et al. — reduced circulating IL-17 and TNF-α alongside elevated IL-10 in the treatment group — is consistent with this mechanistic shift. The IL-10 elevation is particularly notable: IL-10 is the principal anti-inflammatory output of Treg activity and the cytokine most directly associated with autoimmune suppression in RA models.

Vital Yogurts Connection: Monterey

Vital Yogurts Monterey is formulated around the Lacticaseibacillus casei lineage — the designated primary culture in the multi-organism formula used in this trial. The product exists specifically because of the breadth of the L. casei evidence base in mucosal immune signaling, and this study represents one of the most direct clinical demonstrations of that activity in an autoimmune context.

Monterey is available across three inoculation tiers. The Valley tier delivers a single inoculation at 20 billion CFU in a creamy fresh milk blend. The Reserve tier uses double inoculation at 40 billion CFU in a creamier fresh milk blend. The Summit tier is triple-inoculated at 60 billion CFU in the creamiest fresh milk blend. The trial administered the culture formula daily at a total CFU dose most comparable to the Reserve and Summit tiers, making those the most relevant reference points for anyone evaluating Monterey in the context of this research's design and dosing.

Protocol Implications

The most clinically important finding in the protocol is the 12-month follow-up data. The control group showed partial initial response to DMARDs, then reverted toward baseline disease activity by month 12. The culture-formula group reached a DAS28 of 2.3 ± 0.4 — below the near-remission threshold of 2.6 — and sustained it. This is not a story about a short-term symptomatic response; it is a story about trajectory divergence that widened over time. The hazard ratio of 2.703 for remission in the culture group was the strongest independent predictor in the model — stronger than any DMARD variable measured. That kind of trajectory divergence requires sustained, daily consumption over months, not episodic use over weeks. For live fermented dairy, the practical application from this data is direct: a single daily serving consumed with or immediately after a meal — which moderates gastric acid exposure and improves culture survival through the upper GI tract — taken consistently over a minimum of 24 weeks. That is what the study measured. That is what produced the remission rate.

Vital Yogurts — Monterey

The culture studied is in Monterey.

Lacticaseibacillus casei — BLn2401

Monterey is built around L. casei — the primary culture in this trial's formula. In this 12-month RCT, L. casei BLn2401 alongside standard DMARD therapy produced a 61.2% remission rate at 24 weeks and sustained near-remission DAS28 scores at 12 months, compared to 12% remission and disease reversion in the control group. Daily consumption of a live fermented milk delivering L. casei is what the protocol looked like.

Valley — 20B CFU Reserve — 40B CFU Summit — 60B CFU

Shop Monterey

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your diet or supplement routine. The studies cited are referenced for informational context; Vital Yogurts makes no therapeutic or disease treatment claims.